
  
    
      
        
        Nevirapine_NNP and_CC efavirenz_NN are_VBP the_DT most_RBS commonly_RB prescribed_VBN of_IN the_DT class_NN of_IN antiretroviral_NN
        drugs_NNS called_VBD non-nucleoside_JJ reverse_NN transcriptase_NN inhibitors_NNS (_( NNRTIs_NNP )_) ._. Efavirenz_NNP has_VBZ the_DT
        advantage_NN of_IN once-daily_JJ dosing_VBG ._. In_IN a_DT recent_JJ study_NN called_VBD the_DT 2_CD NN_NNP study_NN (_( Lancet_NNP 363_CD :_:
        1253_CD –_NN 1263_CD )_) ,_, it_PRP appeared_VBD to_TO be_VB only_RB marginally_RB superior_JJ to_TO nevirapine_NN in_IN terms_NNS of_IN clinical_JJ
        success_NN and_CC virological_JJ suppression_NN ._. Van_NNP Leth_NNP and_CC colleagues_NNS have_VBP now_RB shown_VBN that_IN while_IN
        nevirapine_NN and_CC efavirenz_NN both_DT raise_NN high-density_JJ lipoprotein_NN (_( HDL_NNP )_) cholesterol_NN (_( the_DT “ good_NN”
        type_NN of_IN cholesterol_NN )_) ,_, the_DT overall_JJ lipid_NN profile_NN is_VBZ better_JJR with_IN nevirapine_NN than_IN with_IN
        efavirenz_NN ._.
        “ These_DT data_NNS suggest_VBP that_DT nevirapine_NN may_MD be_VB preferable_JJ to_TO efavirenz_NN in_IN HIV-infected_NNP
        adults_NNS with_IN other_JJ cardiovascular_JJ risk_NN factors_NNS ,_,” says_VBZ the_DT study_NN 's_POS academic_JJ editor_NN ,_, Andrew_NNP
        Carr_NNP of_IN St_NNP ._. Vincent_NNP 's_POS Hospital_NNP in_IN Darlinghurst_NNP ,_, Australia_NNP ._. “ However_RB ,_, perceived_VBD
        cardiovascular_JJ risk_NN is_VBZ only_RB one_CD factor_NN that_WDT would_MD affect_VB the_DT choice_NN between_IN these_DT two_CD
        drugs_NNS ._.”
        Van_NNP Leth_NNP and_CC colleagues_NNS prospectively_RB analyzed_VBD the_DT lipids_NNS of_IN patients_NNS enrolled_VBD in_IN the_DT
        2_CD NN_NNP study_NN ,_, a_DT randomized_JJ ,_, open-label_JJ efficacy_NN study_NN that_WDT included_VBD adults_NNS with_IN HIV_NNP who_WP had_VBD
        never_RB been_VBN on_IN antiretroviral_NN drugs_NNS ._. All_DT patients_NNS were_VBD given_VBN stavudine_NN and_CC lamivudine_NN and_CC
        were_VBD then_RB randomized_JJ into_IN three_CD treatment_NN groups_NNS :_: nevirapine_NN ,_, efavirenz_NN ,_, or_CC both_DT ._.
        For_IN the_DT lipid_NN analysis_NN ,_, which_WDT was_VBD preplanned_JJ ,_, the_DT researchers_NNS included_VBD only_RB the_DT
        nevirapine_NN and_CC efavirenz_NN groups_NNS (_( 417_CD and_CC 289_CD patients_NNS ,_, respectively_RB )_) ._. This_DT was_VBD because_IN the_DT
        2_CD NN_NNP study_NN showed_VBD that_IN simultaneous_JJ use_NN of_IN nevirapine_NN and_CC efavirenz_NN should_MD be_VB avoided—the_NN
        combination_NN is_VBZ associated_VBN with_IN increased_VBN toxicity_NN without_IN increased_VBN efficacy_NN ._. The_DT increase_NN
        in_IN HDL_NNP cholesterol_NN was_VBD significantly_RB higher_JJR with_IN nevirapine_NN than_IN with_IN efavirenz_NN ._. There_EX was_VBD
        a_DT decrease_NN in_IN the_DT ratio_NN of_IN total_JJ cholesterol_NN to_TO HDL_NNP cholesterol_NN with_IN nevirapine_NN and_CC an_DT
        increase_NN with_IN efavirenz_NN ._.
        The_DT study_NN does_VBZ not_RB prove_VB ,_, however_RB ,_, that_IN the_DT rise_NN in_IN HDL_NNP cholesterol_NN seen_VBN with_IN NNRTIs_NNP
        (_( especially_RB nevirapine_NN )_) actually_RB leads_VBZ to_TO a_DT reduction_NN in_IN coronary_JJ heart_NN disease_NN ._. “ There_EX are_VBP
        no_DT vascular_NN functional_JJ data_NNS ,_,” says_VBZ Carr_NNP ,_, “ or_CC clinical_JJ vascular_NN endpoint_NN data_NNS that_WDT confirm_VBP
        that_IN the_DT statistically_RB significant_JJ lipid_NN differences_NNS observed_VBD are_VBP clinically_RB
        significant_JJ ._.”
        The_DT study_NN was_VBD funded_VBN by_IN Boehringer_NNP Ingelheim_NNP ,_, the_DT manufacturer_NN of_IN nevirapine_NN ._. The_DT
        authors_NNS clearly_RB state_VBP that_IN the_DT company_NN had_VBD “ a_DT nonbinding_VBG input_NN on_IN issues_NNS of_IN study_NN design_NN
        and_CC analyses_NNS” but_CC it_PRP had_VBD “ no_DT influence_NN on_IN reporting_NN of_IN the_DT data_NNS or_CC the_DT decision_NN to_TO
        publish_VB ._.”
        Despite_IN its_PRP$ limitations_NNS ,_, van_NN Leth_NNP and_CC colleagues_NNS '_POS study_NN “ moves_VBZ clinicians_NNS and_CC patients_NNS
        away_RB from_IN ‘ one-size-fits-all_JJ’ antiretroviral_NN therapy_NN ,_,” says_VBZ Carr_NNP ._. “ It_PRP takes_VBZ us_PRP further_RB
        along_IN the_DT path_NN of_IN choice_NN of_IN antiretroviral_NN therapy_NN being_VBG individualized_JJ according_VBG to_TO other_JJ
        patient_NN comorbidities_NNS and_CC risk_NN factors_NNS ,_, as_RB well_RB as_IN therapy_NN simplicity_NN and_CC side_NN
        effects_NNS ._.”
      
    
  
